Migraine drug satisfaction study ends early – what did we learn?
NCT ID NCT06237062
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 37 migraine patients in the Gulf region who had just started taking erenumab. Researchers measured how satisfied patients were with the treatment over 12 weeks using a questionnaire. The study was observational, meaning patients received their normal care, and was terminated early, so findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- erenumab
- What this could lead to
- If successful, this could show that erenumab improves treatment satisfaction for migraine patients in real-world settings.
- What could go wrong
- This was a small, terminated observational study with only 37 participants, so results may not be reliable or generalizable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?